z-logo
open-access-imgOpen Access
Primary hypokalemic periodic paralysis: Long-term management and complications in a child
Author(s) -
Indar Kumar Sharawat,
Renu Suthar,
Naveen Sankhyan,
Pratibha Singhi
Publication year - 2020
Publication title -
journal of pediatric neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 18
eISSN - 1998-3948
pISSN - 1817-1745
DOI - 10.4103/jpn.jpn_101_19
Subject(s) - hypokalemic periodic paralysis , medicine , hypokalemia , missense mutation , periodic paralysis , muscle weakness , paralysis , acetazolamide , weakness , flaccid paralysis , pediatrics , spironolactone , anesthesia , mutation , surgery , gene , genetics , heart failure , biology
Hypokalemic periodic paralysis (HPP) is a rare genetically determined neuromuscular disorder caused by mutation in skeletal muscles calcium and sodium channels. It presents with recurrent episodes of flaccid paralysis. A 9-year-old girl presented with recurrent episodic flaccid quadriparesis with complete recovery in-between the episodes. Investigations during the acute episode revealed marked hypokalemia with electrocardiogram changes. Next-generation sequencing showed pathogenic missense mutation in CACNA1S gene. She responded well to oral potassium supplementation, acetazolamide, and spironolactone therapy. Muscle weakness in HPP is reversible, and long-term management reduces frequency of paralysis and prevents permanent weakness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here